5,5-bis(bromomethyl)-1,3-dioxane | 22633-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 5,5-bis(bromomethyl)-1,3-dioxane
• CAS: 22633-46-1
• 化学式: C₆H₁₀Br₂O₂
• 分子量: 273.952
• InChiKey: GUNJVNMZQFNSOA-UHFFFAOYSA-N

物化性质

• 沸点：
  289.5±35.0 °C(Predicted)
• 密度：
  1.762±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,5-bis(bromomethyl)-1,3-dioxane 在 Lindlar's catalyst sodium azide 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 1,3-dioxane-5,5-dimethanamine
  参考文献：
  名称：

  A new family of water-soluble, third-generation antitumor platinum complexes

  摘要：

  [1,1-Cyclobutanedicarboxylato(2)-O,O'](1,3-dioxane-5,5-dimethan amine- N,N')platinum(II), 3a, a third generation, very water-soluble platinum complex, has been synthesized along with several of its analogues. All members of the new family contain a 1,3-dioxane or 1,3-dioxolane-1,3-diamine as their basic ligand, a moiety which contributes to their increased water solubility, and a bidentate acid ligand, which is responsible for their good stability. They were all easily crystallized and characterized by 1H NMR and elemental analysis, and the parent complex 3a was further characterized by 13C NMR. Their very desirable physical properties combined with their broad spectrum of antitumor activity and reduced toxicity make them good candidates of further development.

  DOI：

  10.1021/jm00129a008
• 作为产物：
  描述：

  二溴新戊二醇 在 盐酸 、 聚合甲醛 作用下， 生成 5,5-bis(bromomethyl)-1,3-dioxane
  参考文献：
  名称：

  Water soluble platinum complexes of novel malonate derivatives

  摘要：

  本披露描述了一种新型丙二酸衍生物的水溶性铂配合物，具有抑制哺乳动物肿瘤生长的特性。

  公开号：

  US04870070A1

文献信息

• Synthesis of Dithiane-Based Photolabile Molecular Systems
  作者：Andrei Kutateladze、Oleg Mitkin、Yongqin Wan、Alexei Kurchan

  DOI：10.1055/s-2001-15057

  日期：——

  Synthesis 2001, No. 8, 18 06 2001. Article Identifier: 1437-210X,E;2001,0,08,1133,1142,ftx,en;C00801SS.pdf. © Georg Thieme Verlag Stuttgart · New York ISSN 0039-7881 Abstract: Synthesis of photolabile molecular systems based on lithiodithiane addition to carbonyl compounds is described. Dithianes of the spiro structure, e.g., 2,4,8,10-tetrathiaspiro[5.5]undecane and 2,4-dithia-8,10-dioxaspiro[5.5]undecane

  Synthesis 2001, No. 8, 18 06 2001. 文章标识符：1437-210X,E;2001,0,08,1133,1142,ftx,en;C00801SS.pdf。© Georg Thieme Verlag Stuttgart · 纽约 ISSN 0039-7881 摘要：描述了基于二硫代锂加成羰基化合物的光不稳定分子系统的合成。螺结构的二噻烷，例如 2,4,8,10-四噻螺[5.5]十一烷和 2,4-二噻-8,10-二氧杂螺[5.5]十一烷被用作系链，因此允许采用模块化方法来构建一组不同的光裂解分子。发现从简单取代的苯甲醛到甲酰化苯并冠醚、碳水化合物或杯芳烃的各种羰基化合物都适用于这种化学。
• Preparation and characterization of diiron diselenolato complexes containing a dioxane ring as models for [FeFe]-hydrogenases
  作者：Mohammad K. Harb

  DOI：10.1007/s11243-014-9844-7

  日期：2014.9

  Fe3(CO)12 with 5,5-bis(selenocyanatomethyl)-2,2-dimethyl-l,3-dioxane. Both complexes were characterized by spectroscopic techniques. In addition, the solid state structure of [Fe2(μ-Se2C6H10O2)(CO)6] was determined by single-crystal X-ray analysis.Graphical AbstractDiiron complexes containing dioxan ligand (5 and 6) of the [FeFe]-hydrogenase active site have been synthesized and characterized. The presence

  在回流的 THF 中用 5,5-双（硒氰基甲基）-1,3-二恶烷处理 Fe3(CO)12，得到 [Fe2(μ-Se2C6H10O2)(CO)6]。二甲基类似物 [Fe2(μ-Se2C6H10O2Me2)(CO)6] 由 Fe3(CO)12 与 5,5-双（硒氰基甲基）-2,2-二甲基-1,3-二恶烷反应得到。两种配合物均通过光谱技术表征。此外，[Fe2(μ-Se2C6H10O2)(CO)6] 的固态结构是通过单晶 X 射线分析确定的。 图文摘要 Diiron 配合物含有 [FeFe]-氢化酶活性的二恶烷配体（5 和 6）站点已被合成和表征。O 原子在桥接铁核中的存在使得它所连接的五元环在空气中更加稳定。
• Synthesis of cisplatin analogs
  申请人：American Cyanamid Company

  公开号：US04808730A1

  公开（公告）日：1989-02-28

  This disclosure sets forth a novel process for producing cisplatin analogs which possess antitumor activity.

  这份披露说明了一种生产具有抗肿瘤活性的顺式铂类似物的新方法。
• NOVEL PHOSPHODIESTERASE INHIBITORS
  申请人：Felding Jakob

  公开号：US20100099688A1

  公开（公告）日：2010-04-22

  The present invention relates to a compound according to formula I, wherein X, A, G, E, R 1 , R 2 , R 3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及公式I所示的化合物，其中X，A，G，E，R1，R2，R3如下所示；以及其药学上可接受的盐，水合物，N-氧化物或溶剂化物。本发明还涉及上述化合物在治疗中的使用，包括含有该化合物的药物组合物，用于治疗疾病（例如皮肤疾病）的方法，以及该化合物在制药中的使用。
• Phosphodiesterase inhibitors
  申请人：Leo Pharma A/S

  公开号：US08338431B2

  公开（公告）日：2012-12-25

  The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及公式I所示的化合物，其中X，A，G，E，R1，R2，R3如所示；以及其药学上可接受的盐，水合物，N-氧化物或溶剂化物。本发明还涉及上述化合物用于治疗的用途，包括制成药物组合物的制备方法，用于治疗疾病（例如皮肤疾病）的方法，以及用于制造药物的上述化合物的用途。